{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=28&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Cincinnati",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 10549,
    "total_pages": 1055,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=29&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=27&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T08:41:14.332Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02100683",
      "title": "Nit-Occlud PDA Post-Approval Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Patent Ductus Arteriosus (PDA)"
      ],
      "interventions": [
        {
          "name": "PDA Coil",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "PFM Medical, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 184,
      "start_date": "2014-08",
      "completion_date": "2022-08-10",
      "has_results": false,
      "last_update_posted_date": "2022-10-04",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 11,
      "location_summary": "Loma Linda, California • Los Angeles, California • Madera, California + 8 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02100683"
    },
    {
      "nct_id": "NCT03311854",
      "title": "A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macrophage Activation Syndrome",
        "Lymphohistiocytosis, Hemophagocytic",
        "Arthritis, Juvenile",
        "Adult Onset Still Disease"
      ],
      "interventions": [
        {
          "name": "Emapalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-02-20",
      "completion_date": "2020-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-05-17",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311854"
    },
    {
      "nct_id": "NCT05438329",
      "title": "First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "DB-1305/BNT325",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "BNT327",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "DualityBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1123,
      "start_date": "2022-07-19",
      "completion_date": "2027-09-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 42,
      "location_summary": "Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more",
      "locations": [
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05438329"
    },
    {
      "nct_id": "NCT02296502",
      "title": "Comparison of DSM-IV-TR and DSM-5 for ASD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "DSM",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 439,
      "start_date": "2014-11",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2019-03-11",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Columbia, Missouri • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02296502"
    },
    {
      "nct_id": "NCT04980872",
      "title": "A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)"
      ],
      "interventions": [
        {
          "name": "Miransertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "2 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-11-02",
      "completion_date": "2030-02-07",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980872"
    },
    {
      "nct_id": "NCT00312039",
      "title": "Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Elvucitabine",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2006-03-31",
      "completion_date": "2007-10-31",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00312039"
    },
    {
      "nct_id": "NCT03597503",
      "title": "Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "SPN-810",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2018-07-31",
      "completion_date": "2020-01-22",
      "has_results": true,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 38,
      "location_summary": "Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03597503"
    },
    {
      "nct_id": "NCT00241969",
      "title": "Behavioral & Nutritional Treatment to Help CF Preschoolers Grow",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Pancreatic Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Behavioral and Nutrition Treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Education and Attention Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "2 Years to 6 Years"
      },
      "enrollment_count": 78,
      "start_date": "2006-01",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2018-05-22",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Ann Arbor, Michigan • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241969"
    },
    {
      "nct_id": "NCT01416441",
      "title": "Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tourette's Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "7 Years to 18 Years"
      },
      "enrollment_count": 170,
      "start_date": "2011-10-19",
      "completion_date": "2014-03-13",
      "has_results": true,
      "last_update_posted_date": "2021-10-07",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 36,
      "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01416441"
    },
    {
      "nct_id": "NCT03969641",
      "title": "Safety of RIV4 Versus IIV4 in Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Safety",
        "Adverse Event Following Immunisation",
        "Birth Outcomes"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Recombinant Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 384,
      "start_date": "2019-09-05",
      "completion_date": "2021-09-29",
      "has_results": true,
      "last_update_posted_date": "2023-01-11",
      "last_synced_at": "2026-11-04T08:41:14.332Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03969641"
    }
  ]
}